COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

NCL News Archive

Monday, October 12, 2020

Submissions Open to COVID-19 Applications

The NCL is temporarily opening its Assay Cascade characterization program to nanotech concepts with a focus on COVID-19. Those interested in applying for a COVID-19 concept can complete the NCL White Paper application found on our website. Submissions deadlines will follow the same quarterly submissions for cancer concepts—March, June, September & December.

The next deadline for... View Post


Monday, October 5, 2020

Novel prodrug platform enables drug delivery to lymphatic system

Researchers at the NCL have developed a nanotechnology platform which targets the lymphatic system via scavenger receptor A1 (SR-A1), a cell surface receptor highly expressed on cells lining the vasculature and myeloid cells within lymph nodes. By targeting the lymphatics, this poly(L-lysine succinylated) (PLS) polymer could provide new treatment options for a variety of diseases including... View Post


Thursday, September 24, 2020

New Assay Cascade Awardees Announced - September 2020

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post


Tuesday, September 22, 2020

Next Application Deadline - December 1, 2020

The next deadline for application to NCL’s Assay Cascade characterization program is December 1, 2020. Visit our application and instructions page to download the template and review the evaluation criteria: https://ncl.cancer.gov/working-ncl/ncl-assay-cascade-application-process

Have questions about the application, evaluation criteria, or the overall process? Please... View Post


Monday, September 21, 2020

Hiring Formulation Scientist

The Nanotechnology Characterization Lab (NCL) is seeking a Formulation Scientist to join our team. 

The scientist in this position is expected to have formulation experience of nanotechnology-based drug delivery platforms, including targeted nanotechnology constructs, macromolecular prodrug systems, polymeric, lipidic, micelle, liposome, and/or metallic formulations.... View Post


Friday, July 31, 2020

Nanotechnology—Over a Decade of Progress and Innovation

The US FDA released a report summarizing the agency's efforts in the field of nanotechnology. The report "Nanotechnology—Over a Decade of Progress and Innovation" can be accessed online here: https://www.fda.gov/media/140395/download. You can also watch Dr. Anil Patri, Chair of the FDA Nanotechnology Task Force, present on the topic August 13th. Details and registration for thew webinar are... View Post


Friday, July 31, 2020

Assay Cascade Awardees Announced - July 2020

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post


Monday, April 13, 2020

Immunology Webinar Series

UPDATE--The online Immunology Workshop originally planned for June 8-12 and 15-18, 2020 has been reschdeuled to May 18-22, 25-28, 2020. The meeting time (11am-1pm EDT) and workshop agenda remain unchanged.  

FREE Online Immunology Workshop

Molecular and Cellular Immunology: From Basics to Applications in Preclinical... View Post


Thursday, March 26, 2020

Bioequivalence Studies: Doxil vs Sun Pharma and Abraxane vs Genexol-PM

The NCL recently completed a 2.5 year interagency collaboration with the US Food and Drug Administration (FDA) to evaluate the bioequivalence of marketed nanomedicines. The complexity of nanomedicine drug formulations poses unique scientific challenges. And, with the influx of generic versions of several nanomedicines now nearing clinical evaluation, these formulations pose unique regulatory... View Post


Monday, March 9, 2020

New Assay Cascade Awardees Announced

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post


Pages